Loading...
XJPX
4512
Market cap58mUSD
Jul 10, Last price  
279.00JPY
1D
1.45%
1Q
-17.21%
Jan 2017
12.05%
Name

Wakamoto Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4512 chart
P/E
42.62
P/S
0.98
EPS
6.55
Div Yield, %
1.09%
Shrs. gr., 5y
—
Rev. gr., 5y
2.18%
Revenues
9.91b
+27.18%
10,181,164,00010,081,276,0009,779,708,0009,671,815,0009,429,946,0009,924,168,00010,314,297,00010,613,425,00011,194,262,00010,833,025,00010,900,874,00010,741,975,00010,917,899,0008,894,837,0008,383,144,0008,660,377,0007,738,426,0007,789,462,0009,906,841,000
Net income
227m
+252.60%
406,893,000351,361,00048,518,000-425,505,000-222,170,000183,344,000844,791,00083,343,00020,512,00094,745,000125,956,000-181,280,000-1,656,539,000-601,856,000238,543,000138,256,000108,959,00064,440,000227,215,000
CFO
-487m
L-17.81%
894,171,000824,582,000489,390,000346,513,000589,256,0001,199,890,0001,629,172,0001,175,302,000594,303,0001,098,285,000555,706,000-114,493,000-155,064,000163,438,000339,174,000631,920,000-107,338,000-592,454,000-486,912,000
Dividend
Mar 30, 20263 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Headquartered in Tokyo, Japan, Wakamoto Pharmaceutical Co., Ltd. specializes in the production and distribution of both prescription and over-the-counter pharmaceuticals across the country. Their diverse offerings include Strong Wakamoto, a widely recognized gastrointestinal aid formulated to enhance digestion, regulate intestinal health, and supplement nutrition. Additionally, the company provides AVANTBISE oral tablets, a dietary supplement designed to rebalance the oral microbiome, as well as various medicated toothpastes. Founded in 1929, the enterprise was initially known as Society for Nutrition and Raising Children Co., Ltd. before formally changing its name to Wakamoto Pharmaceutical Co., Ltd. in July 1943.
URL
https://www.wakamoto-pharm.co.jp/
IPO date
May 16, 1949
Employees
403
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT